Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



New Benzimidazole derivatives as Inhibitors of Pteridine Reductase 1: Design, Molecular docking study and ADMET prediction.

Shraddha Phadke, Rakesh Somani, Devender Pathak.




Abstract
Cited by 7 Articles

Pteridine reductase 1 (PTR1) is a unique enzyme required for survival of Leishmania species, a causative organism for the disease Leishmaniasis. We herein report the design, docking and ADMET prediction studies of 2-substituted-5-[(6-substituted-1H-benzimidazol-2yl)methyl]azole derivatives (B1-B14) as PTR 1 inhibitors. Molecular docking studies showed good binding interaction of the compounds with the active site of the Pteridne reductase from L. major with compounds B5 and B12 showing docking scores of -61.5232 and -62.5897 respectively which were comparable with the original ligand, dihydrobiopterin. Large substituents on the azole ring as well as substitutions on 6th position of benzimidazole ring were found favorable for interaction with PTR1 active site. Physicochemical properties, bioactivity prediction and toxicity profiles of the compounds were studied using molinspiration and admetSAR web servers. All compounds followed Lipinski’s rule of five and can be considered as good oral candidates. Bioactivity prediction indicated the compounds to be enzyme inhibitor thus the rationale of designing PTR 1 inhibitors was met. Most of the compounds were predicted to have good ADMET properties in terms of GI absorption, absence of P-glycoprotein interaction, and LD50 values in rats. The designed molecules can be further explored for their anti-leishmanial activity.
Keywords Pteridine Reductase 1, Leishmaniasis, benzimidazole derivatives, docking studies, ADMET, druglikeness.

Key words: Pteridine Reductase 1, Leishmaniasis, benzimidazole derivatives, docking studies, ADMET, drug likeness.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.